setrusumab + zoledronic acid (optional)
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteogenesis Imperfecta, Type I
Conditions
Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
Trial Timeline
Sep 11, 2017 → Nov 12, 2020
NCT ID
NCT03118570About setrusumab + zoledronic acid (optional)
setrusumab + zoledronic acid (optional) is a phase 2 stage product being developed by Ultragenyx Pharmaceutical for Osteogenesis Imperfecta, Type I. The current trial status is completed. This product is registered under clinical trial identifier NCT03118570. Target conditions include Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03118570 | Phase 2 | Completed |
Competing Products
16 competing products in Osteogenesis Imperfecta, Type I
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide (FORTEO) + Placebos | Eli Lilly | Approved | 85 |
| Zoledronic Acid | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Phase 3 | 77 |
| Romosozumab + Bisphosphonate | Amgen | Phase 3 | 76 |
| Romosozumab | Amgen | Phase 1 | 32 |
| Denosumab | Amgen | Phase 3 | 76 |
| Denosumab + Alternative osteoporosis medications | Amgen | Phase 3 | 76 |
| Fresolimumab | Sanofi | Phase 1 | 32 |
| SAR439459 + Placebo | Sanofi | Phase 1 | 32 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2/3 | 60 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| Bisphosphonate + Setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 72 |